Viral hepatitis in incarcerated adults: A medical and public health concern

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 1024-1031

  Hunt, Douglas R ^a   Saab, Sammy ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DIAMORPHINE; HEPATITIS VACCINE; METHADONE; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; COMBINATION CHEMOTHERAPY; CONDOM; DRUG DEPENDENCE; DRUG MEGADOSE; HEALTH CARE DELIVERY; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HIV EDUCATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MORBIDITY; MORTALITY; PATIENT COUNSELING; PRIORITY JOURNAL; PRISON; PRISONER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; SEROPREVALENCE; SEXUAL BEHAVIOR; SHORT COURSE THERAPY; SUBSTANCE ABUSE; TATTOO; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; VACCINATION; VIRUS HEPATITIS; VIRUS TRANSMISSION; ADULT; DISEASE TRANSMISSION; HEPATITIS, VIRAL, HUMAN; PREVENTION AND CONTROL; PROCEDURES; PUBLIC HEALTH; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRANSMISSION; TRENDS;

ADULT; DISEASE TRANSMISSION, INFECTIOUS; HEPATITIS, VIRAL, HUMAN; HUMANS; MORBIDITY; PRISONERS; PUBLIC HEALTH; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SURVIVAL RATE; UNITED STATES; VACCINATION; VIRAL HEPATITIS VACCINES;

EID: 65449159422     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.143     Document Type: Review

References (73)

1. Bureau of Justice Statistics Bulletin (US). Prison Inmates at Midyear 2007. Available from: http://www.ojp.usdoj.gov/bjs/pub/pdf/pim07.pdf. Document number NCJ 221944. June 2008.
2. Bureau of Justice Statistics Bulletin (US). Probation and Parole in the United States 2006. Available from: http://www.ojp.usdoj.gov/bjs/pub/pdf/ppus06. pdf. Document number NCJ 220218. December 2007.
3. Bureau of Justice Statistics Bulletin (US). Prisoners in 2006. Available from: http://www.ojp.usdoj.gov/bjs/pub/pdf/p06.pdf. Document number NCJ 219416. December 2007.
4. Hammett TM. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. Am J Public Health 2006;96:974-8.
5. National Commission on Correctional Health Care. Health Status of Soon-To-Be-Released Inmates: A Report to Congress Volume 1. National Commission on Correctional Health Care: Washington, DC, 2002.
6. Vescio MF, Longo B, Babudieri S et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health 2008;62:305-13.
7. Bureau of Justice Statistics Bulletin (US). Recidivism of Prisoners Released in 1994. Available from: http://www.ojp.usdoj.gov/bjs/pub/pdf/rpr94. pdf. Document number NCJ 193427. June 2002.
8. McGovern BH, Wurcel A, Kim AY et al. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis 2006;42:1663-70.
9. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releases from US correctional facilities, 1997. Am J Public Health 2002;92:189-94.
10. Charuvastra A, Stein J, Schwartzapfel B et al. Hepatitis B vaccination practices in state and federal prisons. Public Health Rep 2001;116:203-9.
11. Weinbaum C, Lyeia R, Margolis H. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52 (RR-1):1-33.
12. Latimer WW, Moleko AG, Melnikov A et al. Prevalence and correlates of hepatitis A among adult drug users: the significance of incarceration and race/ethnicity. Vaccine 2007;25:7125-31.
13. Centers for Disease Control and Prevention. Disease Burden from Hepatitis A, B, and C in the United States. Available from: http://www.cdc.gov/ncidod/ diseases/hepatitis/resource/PDFs/disease-burden.pdf. Atlanta, GA, 2006.
14. Khan AJ, Simard EP, Bower WA et al. Ongoing transmission of hepatitis B virus infection among inmates at a state correctional facility. Am J Public Health 2005;95:1793-9.
15. Solomon L, Flynn C, Muck K et al. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health 2004;81:25-37.
16. Macalino GE, Vlahov D, Sanford-Colby S et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C infections among males in Rhode Island prisons. Am J Public Health 2004;94:1218-23.
17. Neff MJ. Practice guidelines: CDC updates guidelines for prevention and control of infections with hepatitis viruses in correctional settings. Am Fam Physician 2003;67:2620-5.
18. McQuillan GM, Coleman PJ, Kruszon-Moran D et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-8.
19. Adjei AA, Armah HB, Gbagbo F et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and oF cers in Ghana: a national multicenter study. BMC Infect Dis 2008;8:33.
20. Allwright S, Bradley F, Long J et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ 2000;321:78-82.
21. Malliori M, Sypsa V, Psichogiou M et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction 2002;93:243-51.
22. Devasia RA, Jones TF, Kainer MA et al. Two community hepatitis B outbreaks: an argument for vaccinating incarcerated persons. Vaccine 2006;24:1354-8.
23. Federal Bureau of Prisons - Clinical Practice Guidelines: Guidelines for the Prevention and Treatment of Viral Hepatitis Available from: http://www.bop.gov/news/PDFs/hepatitis.pdf. October 2005.
24. Centers for Disease Control and Prevention. Hepatitis B outbreak in a state correctional facility, 2000. MMWR Morb Mortal Wkly Rep 2001;50:529-32.
25. Fox RK, Currie SL, Evans J et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis 2005;41:177-86.
26. Spaulding AC, Weinbaum CM, Lau DT et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006;144:762-9.
27. Baillargeon J, Wu H, Kelley MJ et al. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health 2003;117:43-8.
28. Hellard ME, Aitken CK, Hocking JS. Tattooing in prisons - not such a pretty picture. Am J Infect Control 2007;35:477-80.
29. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect 2004;132:409-15.
30. Hand WL, Vasquez Y. Risk factors for hepatitis C on the Texas-Mexico border. Am J Gastroenterol 2005;100:2180-5.
31. Babudieri S, Longo B, Sarmati L et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol 2005;76:311-7.
32. Christensen PB, Krarup HB, Niesters HGM et al. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol 2000;16:1043-9.
33. Samuel MC, Doherty PM, Bulterys M et al. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001;127:475-84.
34. Briggs ME, Baker C, Hall R et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration Medical Center. Hepatology 2001;34:1200-5.
35. Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine 2001;80:134-51.
36. Seal DW, Margolis AD, Morrow KM et al. Substance use and sexual behavior during incarceration among 18- to 29-year old men: prevalence and correlates. AIDS Behav 2008;12:27-40.
37. Nacci PL, Kane TR. e incidence of sex and sexual aggression in federal prisons. Fed Probation 1983;47:31-6.
38. Saum CA, Surratt H, Inciardi JA et al. Sex in prison: exploring the myths and realities. Prison J 1995;75:413-30.
39. Samuel MC, Bulterys M, Jenison S et al. Tattoos, incarceration and hepatitis B and C among street-recruited injection drug users in New Mexico, USA: update. Epidemiol Infect 2005;133:1146-8.
40. Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. J Am Acad Dermatol 2006;55:413-21.
41. Butler T, Milner L. e 2001 New South Wales Inmate Health Survey. Available from: http://www.justicehealth.nsw.gov.au/pubs/Inmate-Health-Survey- 2001.pdf. Corrections Health Service: Sydney, 2003.
42. Lok AS, McMahon BJ. AASLD practice guidelines: chronic hepatitis B. Hepatology 2007;45:507-39.
43. Pisu M, Meltzer MI, Lyerla R. Cost-e8 ectiveness of hepatitis B vaccination of prison inmates. Vaccine 2002;21:312-21.
44. May JP, Williams EL. Acceptability of condom availability in a US jail. AIDS Educ Prev 2002;14:85-91.
45. Moller L, Stover H, Jurgens R et al. Health in prisons: a WHO guide to the essentials in prison health. World Health Organization Europe. Available at: http://www.euro.who.int/document/e90174.pdf. Copenhagen, Denmark, 2007.
46. Dolan K, Rutter S, Wodak AD. Prison-based syringe exchange programmes: a review of international research and development. Addiction 2003;98:153-8.
47. Okie S. Sex, drugs, prisons, and HIV. N Engl J Med 2007;356:105-8.
48. Betteridge G. Public health agency says prison needle exchanges reduce risk, do not threaten safety or security. HIV AIDS Policy Law Rev 2007;12:20-2.
49. Levy MH, Treloar C, McDonald RM et al. Prisons, hepatitis C and harm minimization. Med J Aust 2007;186:647-9.
50. Stallwitz A, Stover H. e impact of substitution treatment in prisons - a literature review. Int J Drug Policy 2007;18:464-74.
51. Dolan KA, Shearer J, White B et al. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005;100:820-8.
52. Martin SS, Butzin CA, Saum C et al. Three-year outcomes of therapeutic community treatment for drug-involved o8 enders in Delaware from prison to work release to a3 ercare. Prison J 1999;79:294-320.
53. Wolitski RJ. Relative eF cacy of a multisession sexual risk-reduction intervention for young men released from prisons in 4 states. Am J Public Health 2006;96:1854-61.
54. Taylor RM, Davern T, Munoz S et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology 2006;44:1589-97.
55. Conklin TJ, Lincoln T, Flanigan TP. A public health model to connect correctional health care with communities. Am J Public Health 1998;88:1249-50.
56. Allen SA, Spaulding AC, Osei AM et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003;138:187-90.
57. Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology 2008;48:1387-1395.
58. Maru D, Bruce RD, Basu S et al. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and e8 ectiveness for challenging treatment populations. Clin Infect Dis 2008;47:952-61.
59. Batey RG, Jones T, McAllister C. Prisons and HCV: a review and a report on an experience in New South Wales Australia. Int J Prison Health 2008;4:156-63.
60. Ampofo W, Nii-Trebi N, Ansah J et al. Prevalence of blood-borne infectious diseases in blood donors in Ghana. J Clin Microbiol 2002;40:3523-5.
61. Singh S, Prasad R, Mohanty A. High prevalence of sexually transmitted and blood-borne infections amongst the inmates of a district jail in Northern India. Int J STD AIDS 1999;10:475-8.
62. Behal R, Jain R, Behal KK et al. Seroprevalence and risk factors for hepatitis B virus infection among general population in Northern India. Arch Gastroenterol 2008;45:137-40.
63. German V, Giannakos G, Kopterides P et al. Serologic indices of hepatitis B virus infection in military recruits in Greece (2004-2005). BMC Infect Dis 2006;6:163.
64. Butler T, Boonwaat L, Hailstone S et al. The 2004 Australian prison entrants'blood-borne virus and risk behavior survey. Aust N Z J Public Health 2007;31:44-50.
65. Tawk HM, Vickery K, Bisset L, et al., Infection in Endoscopy Study Group. The current pattern of hepatitis B virus infection in Australia. J Viral Hepat 2006;13:206-15.
66. O'Connell T, Thornton L, O'Flanagan D et al. Prevalence of hepatitis B anti-core antibody in the Republic of Ireland. Epidemiol Infect 2000;125:701-4.
67. Nascimento MC, Mayaud P, Sabino EC et al. Prevalence of hepatitis B and C serological markers among rst-time blood donors in Brazil: a multicenter serosurvey. J Med Virol 2008;80:53-7.
68. Catalan-Soares BC, Almeida RT, Carneiro-Proletti BF. Prevalence of HIV-1/2, HTLV-1/2, hepatitis B virus, hepatitis C virus, Treponema pallidum and Trypanosomacruzi among prison inmates at Manhuacu, Minas Gerais State, Brazil. J Braz Soc Trop Med 2000;33:27-30.
69. Lieb S, Trepka MJ, Thompson DR et al. Men who have sex with men: estimated population sizes and mortality rates by race/ethnicity, Miami-Dade county, Florida. J Acquir Immune Dec Syndr 2007;46:485-90.
70. Office of Applied Studies, Substance Abuse and Mental Health Services Administration e National Survey on Drug Use and Health. Injection Drug Use Update: 2002 and 2003. Available from: http://www.oas.samhsa.gov/2k5/ivdrug/ ivdrug.pdf. Research Triangle Park, NC, 2005.
71. Frischer M, Leyland A, Cormack R et al. Estimating the population prevalence of injection drug use and infection with human immunodeficiency virus among injection drug users in Glasgow, Scotland. Am J Epidemiol 1993;138:170-81.
72. Bureau of Justice Statistics Bulletin (US). Drug Use and Dependence, State and Federal Prisoners, 2004. Available from: http://www.ojp.usdoj.gov/bjs/ pub/pdf/dudsfp04.pdf. Document number NCJ 213530. October 2006.
73. Warner LA, Kessler RC, Hughes M et al. Prevalence and correlates of drug use and dependence in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1995;52:219-29.